Company / SG&A Expense
Glaukos Corp. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$331.7M
FY2025
5-year range
$179.3M / $331.7M
FY2021-FY2025
Trend
+27.0%
vs FY2024
Sector context
#82 of 152
Health Care
What the data says
At $332M, Glaukos Corp.'s sg&a expense ranks #71 of 152 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $171M in FY2020 to $332M in FY2025.
Based on SEC 10-K filings.
$332M in FY2025 with a 5-year CAGR of +14.1%.
Increased from $224M to $332M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.8%
- 5-Year CAGR
- +14.1%
- 10-Year CAGR
- -
Sector benchmark
#71 of 152 in Health CareTop 46% of 152This company $331.7M Sector average $182.7B
▼
-99.8% below sector average
Key checks
Key Insights
- Glaukos Corp.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +14.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 27.0% year-over-year.
- Ranks #82 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $331.7M | +27.0% |
| FY2024 | $261.2M | +16.6% |
| FY2023 | $224.1M | +16.1% |
| FY2022 | $192.9M | +7.6% |
| FY2021 | $179.3M | +4.6% |
| FY2020 | $171.4M | -3.0% |
| FY2019 | $176.6M | +47.8% |
| FY2018 | $119.5M | +24.2% |
| FY2017 | $96.3M | +48.7% |
| FY2016 | $64.8M | +47.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026